权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of CRISPR/Cas9-based exon-skipping strategies for the treatment of USH-associated deafness

开发基于 CRISPR/Cas9 的外显子跳跃策略来治疗 USH 相关耳聋

基本信息

批准号：
10688070
负责人：
Zheng-Yi Chen
金额：
$ 69.57万
依托单位：
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-22 至 2027-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10688070
关键词：
Affect Animal Model Auditory Biological Assay Blindness Budgets CRISPR/Cas technology Cell Line Cell Therapy Cell model Cells Classification Clinical Clinical Trials Cochlear Implants Code Communication Coping Skills Data Development Electrophysiology (science)Engineering Excision Exons Foundations Gene Expression Profiling Gene Transduction Agent Generations Genes Genetic Diseases Genomic DNA Genomics Goals Guide RNA Hair Hair Cells Hearing Hereditary Disease Human Inherited Inner Hair Cells Knockout Mice Labyrinth Masks Mediating Messenger RNA Modeling Mus Mutation National Institute on Deafness and Other Communication Disorders Nature Organ of Corti Organoids Patients Persons Phenotype Prevalence Production Proteins Protocols documentation Recovery Research Retina Severities Social Distance Structure Symptoms Technology Testing Therapeutic Time Transgenic Organisms USH1D gene USH2A gene United States Usher Syndrome Wild Type Mouse Work Zebrafish autosomal recessive trait clinical application clinical subtypes current pandemic deaf deafness design early childhood exon skipping frontier genetic deafness genome editing hearing restoration hereditary hearing loss improved in vivo induced pluripotent stem cell mouse model mutant mutation correction novel novel therapeutic intervention pre-clinical protein structure therapeutic genome editing therapeutically effective therapy development tool treatment strategy whole genome

项目摘要

Abstract: Usher syndrome (USH) is the most common form of inherited deaf-blindness, with a prevalence of 1/6.000. Inherited as an autosomal recessive trait, it affects about 15,000 people in the United States and is responsible for 6% of early childhood deafness. Usher syndrome is classified under three clinical subtypes (USH-1, -2 and -3) according to the severity of the symptoms. Approximately 2/3 of the patients with USH suffer from USH2 and USH1, of whom 75% have mutations in the USH2A, USH1D and 1F genes. Because USH affects both major senses, it is a severely debilitating condition, and intense research is crucial to improve coping strategies and develop therapies for the patients. It is particularly devastating during the current pandemic, with social distancing and the wearing of masks making communication nearly impossible. Treatment for USH is limited to cochlear implants, and there is no treatment for the blindness. Development of an effective therapeutic approach for USH has been challenging due to the large size of USH genes. Therefore, there is an unmet need to develop alternative therapeutic strategies. The goal of this project is to develop and test novel therapy approaches for treating recessive deafness in human hair cells of inner ear organoids derived from human induced pluripotent stem cells (hiPSCs) and in USH mouse models by establishing genome editing-based therapeutic strategies for USH and to lay the foundation for moving genome editing approaches closer clinical trials. We have chosen to focus on the most common mutations in the three major USH genes with the following reasons: 1) The USH2A, 1D, and 1F genes are the most common and important USH genes which are responsible for more than 70% human USH cases with significant clinical application; 2) Due to their large size, traditional gene augmentation or addition therapy is hampered as its coding sequence far exceeds the packaging capacity of standard gene therapy vectors; 3) All three USH2A, 1D, and 1F genes contain similar multiple repetitive domains with in frame common mutations in their protein structures, making them potential targets for exon-skipping-based therapies (see Preliminary data); 4) We have obtained exciting data demonstrating restoration of hearing in an Ush2a mouse model using exon skipping strategy with an available mouse model of USH2A and have successfully generated hiPSCs from Usher patients carrying the most common mutations of USH, and established optimized protocols for generation of large numbers of human inner ear organoids with the production of human hair cells derived from these hiPSCs. This proposal leverages the exceptional deafness genomics information and genome editing expertise of collaborators for the development of novel treatments for HL. In this proposal, we will build on our accomplishments and preliminary data by proposing to complete the following specific aims: 1) to develop CRISPR/Cas9- based exon-skipping strategies to rescue hearing in transgenic USH mouse models and 2) to develop exon-skipping by CRISPR/Cas9 editing strategies to rescue USH mutations using inner ear organoids derived from patient hiPSCs. This proposal develops a new strategy utilizing CRISPR/Cas9 editing to skip exons most afflicted by common recessive mutations in USH2A, USH1D and USH1F as treatment to rescue hearing in animal models and restore phenotypes in human patient iPS cells-derived inner ear organoids with the hope of moving these technologies closer to their clinical application.

摘要：Usher综合征（USH）是遗传性聋盲最常见的一种，患病率为1/ 6000。